Oneness Biotech Co Ltd (4743.TWO) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · Taiwan · ISIN TW0004743000

Price
45.65 TWD
Market cap
21.88 bn TWD
P/E (2025)
–
P/S (2025)
169.42
Dividend yield
0.00 %
Net margin
-809.13 %
Return on equity (ROE)
-10.11 %
Return on assets (ROA)
-8.90 %

Oneness Biotech Co Ltd financials

Fiscal year20242025
Revenue117.93 m TWD129.12 m TWD
Gross profit63.03 m TWD39.88 m TWD
Operating income-1.09 bn TWD-799.08 m TWD
EBIT-1.14 bn TWD-1.05 bn TWD
Net income-1.17 bn TWD-1.04 bn TWD
Diluted EPS – continuing operations-2.44 TWD-2.18 TWD

Full history since 2009, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Oneness Biotech Co Ltd

Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation and Organic Food segments. The company offers Fespixon which is a treatment of diabetic foot ulcer; and Bonvadis, a wound care medical device. It also develops FB825, which is in Phase II clinical trial for treating atopic dermatitis and allergic asthma; FB704A which is in Phase II clinical trial for the treatment of rheumatoid arthritis and inhibiting tumor angiogenesis; SNS812, which is in Phase II clinical trial for the treatment of COVID; and SNS851 which is in clinical development for potential applications in metabolic diseases such as obesity, diabetes, hypercholesterolemia, and fatty liver disease. In addition, the company is involved in the management of agriculture cultivation and organic food trading business; and sale of organic food, dietary supplements, and beverages. Oneness Biotech Co., Ltd. was incorporated in 2008 and is headquartered in Taipei, Taiwan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.